Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06617923 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

StatusRecruiting
PhasePhase 2
Started2025-02-06
View on ClinicalTrials.gov ↗

Amendment history

2025-10-24
minor
Study Status, Contacts/Locations v7
Study sites1→2
2025-02-07
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v6
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-02→confirmed 2025-02-06
Study sites0→1
2025-01-22
minor
Study Status, Study Description v5
Re-verified, no change to tracked fields
2025-01-16
minor
Study Identification, Study Status, Study Description v4
Start date2025-01→2025-02
Study title+45 characters
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
2024-12-09
minor
Study Status v3
Start date2024-12→2025-01
Show 2 earlier versions
2024-11-05
minor
Study Status v2
Start date2024-11→2024-12
2024-10-21
minor
Study Status v1
Start date2024-10→2024-11
2024-09-26
minor
Original filing
This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.
Trial Details
NCT Number NCT06617923
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: National Cancer Institute (NCI), Impact Therapeutics
Conditions Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Enrollment 18 participants
Start Date 2025-02-06
Primary Completion 2027-10 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-27